Skip to main content

Briviact FDA Approval History

FDA Approved: Yes (First approved February 19, 2016)
Brand name: Briviact
Generic name: brivaracetam
Company: UCB, Inc.
Treatment for: Epilepsy

Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.

Development timeline for Briviact

DateArticle
Aug 30, 2021Approval UCB Announces Briviact (brivaracetam) Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older
May 14, 2018Approval UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients
Sep 15, 2017Approval FDA Approves New indication for Briviact (brivaracetam) as Monotherapy Treatment of Partial-Onset Seizures in Adults
Feb 19, 2016Approval FDA Approves Briviact (brivaracetam) to Treat Partial Onset Seizures
Jan 21, 2015UCB Announces US and EU Regulatory Filings for the Investigational Antiepileptic Drug Brivaracetam

See also

Briviact (brivaracetam) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer